Legal10 Feb 2026, 07:46 am
Lupin Ltd Resolves Patent Infringement Dispute with Astellas for Mirabegron Product
AI Summary
Lupin Ltd and its wholly owned subsidiary Lupin Pharmaceuticals, Inc., USA, have entered into a Settlement and License Agreement with Astellas. The agreement resolves a patent infringement dispute related to Lupin's product ‘Mirabegron’. According to the terms, Lupin will pay Astellas a total of USD 90 million, which includes a Prepaid Option Payment of USD 75 million and a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027. The settlement allows Lupin to continue selling its Mirabegron product, with the terms of the settlement remaining confidential.
Key Highlights
- Lupin Ltd and Astellas have resolved a patent infringement dispute related to Lupin's product ‘Mirabegron’.
- The resolution includes a payment of USD 90 million by Lupin to Astellas.
- The settlement allows Lupin to continue selling its Mirabegron product.
- The terms of the settlement are confidential.
- The agreement is a Settlement and License Agreement pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations.